Complexity of cancer protease biology: Cathepsin K expression and function in cancer progression

Seminars in Cancer Biology

Volumn 35, Issue , 2015, Pages 71-84

  Verbovšek, Urška ^a   Van Noorden, Cornelis J F ^b   Lah, Tamara T ^a,c  

^a NATIONAL INSTITUTE OF BIOLOGY   (Slovenia)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

Cancer; Cathepsin K; Glioma stem like cell; Invasion; Metastasis

Indexed keywords

CATHEPSIN K; CATHEPSIN K INHIBITOR; PROTEINASE; SCLEROPROTEIN; PEPTIDE HYDROLASE; TUMOR MARKER;

CANCER GROWTH; CANCER PROGNOSIS; CANCER THERAPY; CARCINOMA; CELL TRANSPORT; CLINICAL TRIAL (TOPIC); DIFFERENTIAL DIAGNOSIS; ENZYME ACTIVITY; ENZYME REGULATION; HUMAN; LYSOSOME; MOLECULAR PATHOLOGY; NONHUMAN; PRIMARY TUMOR; PROTEIN EXPRESSION; REVIEW; SARCOMA; SIGNAL TRANSDUCTION; TUMOR INVASION; TUMOR MICROENVIRONMENT; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE COURSE; ENZYMOLOGY; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METASTASIS; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PROGNOSIS; PROTEIN DEGRADATION; TREATMENT OUTCOME;

ANIMALS; BIOMARKERS, TUMOR; CATHEPSIN K; DISEASE PROGRESSION; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYSOSOMES; MOLECULAR TARGETED THERAPY; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASMS; PEPTIDE HYDROLASES; PROGNOSIS; PROTEOLYSIS; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

EID: 84948687704     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2015.08.010     Document Type: Review

References (198)

1. Rawlings N.D., Waller M., Barrett A.J., Bateman A. MEROPS: the database of proteolytic enzymes, their substrates and inhibitors. Nucleic Acids Res. 2014, 42:503-509.
2. Ezkurdia I., Juan D., Rodriguez J.M., Frankish A., Diekhans M., Harrow J., et al. Multiple evidence strands suggest that there may be as few as 19 000 human protein-coding genes. Hum. Mol. Genet. 2014, 23:5866-5878.
3. López-Otín C., Overall C.M. Protease degradomics: a new challenge for proteomics. Nat. Rev. Mol. Cell Biol. 2002, 3:509-519.
4. Puente X.S., Sánchez L.M., Overall C.M., López-Otín C. Human and mouse proteases: a comparative genomic approach. Nat. Rev. Genet. 2003, 4:544-558.
5. Doucet A., Butler G.S., Rodríguez D., Prudova A., Overall C.M. Metadegradomics: toward in vivo quantitative degradomics of proteolytic post-translational modifications of the cancer proteome. Mol. Cell. Proteomics 2008, 7:1925-1951.
6. Turk B., Turk D., Turk V. Protease signalling: the cutting edge. EMBO J. 2012, 31:1630-1643.
7. López-Otín C., Hunter T. The regulatory crosstalk between kinases and proteases in cancer. Nat. Rev. Cancer 2010, 10:278-292.
8. Mason S.D., Joyce J.A. Proteolytic networks in cancer. Trends Cell Biol. 2011, 21:228-237.
9. López-Otín C., Matrisian L.M. Emerging roles of proteases in tumour suppression. Nat. Rev. Cancer 2007, 7:800-808.
10. Lah T.T., Duran Alonso M.B., Van Noorden C.J.F. Antiprotease therapy in cancer: hot or not?. Expert Opin. Biol. Ther. 2006, 6:257-279.
11. Akers J.C., Gonda D., Kim R., Carter B.S., Chen C.C. Biogenesis of extracellular vesicles (EV): exosomes, microvesicles, retrovirus-like vesicles, and apoptotic bodies. J. Neurooncol. 2013, 113:1-11.
12. Nakano I. Engulfing losers by winners in cancer: do cancer stem cells catch eat-me signals from noncancer stem cells?. Future Oncol. 2014, 10:1335-1338.
13. Smith R.E., Farquhar M.G. Lysosome function in the regulation of the secretory process in cells of the anterior pituitary gland. J. Cell Biol. 1966, 1:319-347.
14. Aits S., Jäättelä M. Lysosomal cell death at a glance. J. Cell Sci. 2013, 126:1905-1912.
15. Prasmickaite L., Høgset A., Selbo P.K., Engesaeter B.Ø., Hellum M., Berg K. Photochemical disruption of endocytic vesicles before delivery of drugs: a new strategy for cancer therapy. Br. J. Cancer 2002, 86:652-657.
16. Boelens M.C., Wu T.J., Nabet B.Y., Xu B., Qiu Y., Yoon T., et al. Exosome transfer from stromal to breast cancer cells regulates therapy resistance pathways. Cell 2014, 159:499-513.
17. Brix K., Dunkhorst A., Mayer K., Jordans S. Cysteine cathepsins: cellular roadmap to different functions. Biochimie 2008, 90:194-207.
18. Turk V., Stoka V., Vasiljeva O., Renko M., Sun T., Turk B., et al. Cysteine cathepsins: from structure, function and regulation to new frontiers. Biochim. Biophys. Acta 2012, 1824:68-88.
19. Lenarčič B., Bevec T. Thyropins - new structurally related proteinase inhibitors. Biol. Chem. 1998, 379:105-111.
20. Saftig P., Hunziker E., Wehmeyer O., Jones S., Boyde A., Rommerskirch W., et al. Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin-K-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:13453-13458.
21. Dauth S., Arampatzidou M., Rehders M., Yu D.M.T., Führer D., Brix K. Thyroid cathepsin K: roles in physiology and thyroid disease. Clin. Rev. Bone Miner. Metab. 2011, 9:94-106.
22. Quintanilla-Dieck M.J., Codriansky K., Keady M., Bhawan J., Rünger T.M. Expression and regulation of cathepsin K in skin fibroblasts. Exp. Dermatol. 2009, 18:596-602.
23. Kos J., Sekirnik A., Premzl A., Bergant V.Z., Langerholc T., Turk B., et al. Carboxypeptidases cathepsins X and B display distinct protein profile in human cells and tissues. Exp. Cell Res. 2005, 306:103-113.
24. Perišić Nanut M., Sabotič J., Jewett A., Kos J. Cysteine cathepsins as regulators of the cytotoxicity of NK and T cells. Front. Immunol. 2014, 5:7-9.
25. Lah T.T., Buck M.R., Honn K.V., Crissman J.D., Rao N.C., Liotta L.A., et al. Degradation of laminin by human tumor cathepsin B. Clin. Exp. Metastasis 1989, 7:461-468.
26. Mohamed M.M., Sloane B.F. Cysteine cathepsins: multifunctional enzymes in cancer. Nat. Rev. Cancer 2006, 6:764-775.
27. Droga-Mazovec G., Bojic L., Petelin A., Ivanova S., Romih R., Repnik U., et al. Cysteine cathepsins trigger caspase-dependent cell death through cleavage of bid and antiapoptotic Bcl-2 homologues. J. Biol. Chem. 2008, 283:19140-19150.
28. Tedelind S., Poliakova K., Valeta A., Hunegnaw R., Yemanaberhan E.L., Heldin N.E., et al. Nuclear cysteine cathepsin variants in thyroid carcinoma cells. Biol. Chem. 2010, 391:923-935.
29. Goulet B., Baruch A., Moon N.-S., Poirier M., Sansregret L., Erickson A., et al. A cathepsin L isoform that is devoid of a signal peptide localizes to the nucleus in S phase and processes the CDP/Cux transcription factor. Cell 2004, 14:207-219.
30. Duncan E.M., Muratore-Schroeder T.L., Cook R.G., Garcia B.A., Shabanowitz J., Hunt D.F., et al. Cathepsin L proteolytically processes histone H3 during mouse embryonic stem cell differentiation. Cell 2008, 135:284-294.
31. Santos-Rosa H., Kirmizis A., Nelson C., Bartke T., Saksouk N., Cote J., et al. Histone H3 tail clipping regulates gene expression. Nat. Struct. Mol. Biol. 2008, 16:17-22.
32. Kenig S., Frangež R., Pucer A., Lah T. Inhibition of cathepsin L lowers the apoptotic threshold of glioblastoma cells by up-regulating p53 and transcription of caspases 3 and 7. Apoptosis 2011, 16:671-682.
33. Tholen M., Hillebrand L.E., Tholen S., Sedelmeier O., Arnold S.J., Reinheckel T. Out-of-frame start codons prevent translation of truncated nucleo-cytosolic cathepsin L in vivo. Nat. Commun. 2014, 5:4931.
34. Lecaille F., Brömme D., Lalmanach G. Biochemical properties and regulation of cathepsin K activity. Biochimie 2008, 90:208-226.
35. Brömme D., Wilson S. Role of cysteine cathepsins in extracellular proteolysis. Extracellular Matrix Degradation 2011, 23-52. Springer Berlin Heidelberg, Berlin, Heidelberg. W.C. Parks, R.P. Mecham (Eds.).
36. Li Z., Yasuda Y., Li W., Bogyo M.S., Katz N., Gordon R.E., et al. Regulation of collagenase activities of human cathepsins by glycosaminoglycans. J. Biol. Chem. 2004, 279:5470-5479.
37. Novinec M., Kovacic L., Lenarcic B., Baici A. Conformational flexibility and allosteric regulation of cathepsin K. Biochem. J. 2010, 429:379-389.
38. Li Z., Kienetz M., Cherney M.M., James M.N.G., Brömme D. The crystal and molecular structures of a cathepsin K: chondroitin sulfate complex. J. Mol. Biol. 2008, 383:78-91.
39. Garnero P., Borel O., Byrjalsen I., Ferreras M., Drake F.H., McQueney M.S., et al. The collagenolytic activity of cathepsin K is unique among mammalian proteinases. J. Biol. Chem. 1998, 273:32347-32352.
40. Fonović M., Turk B. Cysteine cathepsins and extracellular matrix degradation. Biochim. Biophys. Acta 2014, 1840:2560-2570.
41. Hou W.-S., Li Z., Büttner F.H., Bartnik E., Brömme D. Cleavage site specificity of cathepsin K toward cartilage proteoglycans and protease complex formation. Biol. Chem. 2003, 384:891-897.
42. Novinec M., Lenarčič B. Cathepsin K: a unique collagenolytic cysteine peptidase. Biol. Chem. 2013, 394:1163-1179.
43. Brömme D., Lecaille F. Cathepsin K inhibitors for osteoporosis and potential off-target effects. Expert Opin. Investig. Drugs 2011, 18:585-600.
44. Everts V., Korper W., Hoeben K.A., Jansen I.D.C., Brömme D., Cleutjens K.B.J.M., et al. Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: differences between calvaria and long bone. J. Bone Miner. Res. 2006, 21:1399-1408.
45. Van Noorden C.J.F., Everts V. Selective inhibition of cysteine proteinases by Z-Phe-AlaCH2F suppresses digestion of collagen by fibroblasts and osteoclasts. Biochem. Biophys. Res. Commun. 1991, 178:178-184.
46. Hou W.S., Li Z., Gordon R.E., Chan K., Klein M.J., Levy R., et al. Cathepsin k is a critical protease in synovial fibroblast-mediated collagen degradation. Am. J. Pathol. 2001, 159:2167-2177.
47. Kollet O., Dar A., Shivtiel S., Kalinkovich A., Lapid K., Sztainberg Y., et al. Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat. Med. 2006, 12:657-664.
48. Rünger T.M., Quintanilla-Dieck M.J., Bhawan J. Role of cathepsin K in the turnover of the dermal extracellular matrix during scar formation. J. Invest. Dermatol. 2007, 127:293-297.
49. Sukhova G.K., Shi G.P., Simon D.I., Chapman H.A., Libby P. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J. Clin. Invest. 1998, 102:576-583.
50. Chiellini C., Costa M., Novelli S.E., Amri E.-Z., Benzi L., Bertacca A., et al. Identification of cathepsin K as a novel marker of adiposity in white adipose tissue. J. Cell. Physiol. 2003, 195:309-321.
51. Kafienah W., Brömme D., Buttle D.J., Croucher L.J., Hollander A.P. Human cathepsin K cleaves native type I and II collagens at the N-terminal end of the triple helix. Biochemistry 1998, 331:727-732.
52. Bühling F., Gerber A., Häckel C., Krüger S., Köhnlein T., Brömme D., et al. Expression of cathepsin K in lung epithelial cells. Am. J. Respir. Cell Mol. Biol. 1999, 20:612-619.
53. Troen B.R. The regulation of cathepsin K gene expression. Ann. N. Y. Acad. Sci. 2006, 1068:165-172.
54. Häckel C., Krüger S., Bühling F., Brömme D., Franke K., Schütze A., et al. Expression of cathepsin K in the human embryo and fetus. Dev. Dyn. 1999, 216:89-95.
55. Jordans S., Jenko-Kokalj S., Kühl N.M., Tedelind S., Sendt W., Brömme D., et al. Monitoring compartment-specific substrate cleavage by cathepsins B, K, L, and S at physiological pH and redox conditions. BMC Biochem. 2009, 10:23.
56. Bernstein H.-G., Bukowska A., Dobrowolny H., Bogerts B., Lendeckel U. Cathepsin K and schizophrenia. Synaspse 2007, 61:252-253.
57. Everts V., Aronson D.C., Beertsen W. Phagocytosis of bone collagen by osteoclasts in two cases of pycnodysostosis. Calcif. Tissue Int. 1985, 37:25-31.
58. Everts V., Hou W.S., Rialland X., Tigchelaar W., Saftig P., Brömme D., et al. Cathepsin K deficiency in pycnodysostosis results in accumulation of non-digested phagocytosed collagen in fibroblasts. Calcif. Tissue Int. 2003, 73:380-386.
59. Turan S. Current research on pycnodysostosis. Intractable Rare Dis. Res. 2014, 3:91-93.
60. Li C.Y., Jepsen K.J., Majeska R.J., Zhang J., Ni R., Gelb B.D., et al. Mice lacking cathepsin K maintain bone remodeling but develop bone fragility despite high bone mass. J. Bone Miner. Res. 2006, 21:865-875.
61. Moore A. Advances in menopausal therapy: the tissue-selective estrogen complex. J. Am. Acad. Nurse Pract. 2013, 25:126-133.
62. Miller K.K. Mechanisms by which nutritional disorders cause reduced bone mass in adults. J. Women's Heal. 2003, 12:145-150.
63. Cardoso L.F., Maciel L.M.Z., de Paula F.J.A. The multiple effects of thyroid disorders on bone and mineral metabolism. Arq. Bras. Endocrinol. Metabol. 2014, 58:452-463.
64. Bhavnani V., Clarke A. Women awaiting hysterectomy: a qualitative study of issues involved in decisions about oophorectomy. BJOG Int. J. Obstet. Gynaecol. 2003, 110:168-174.
65. Derweesh I.H. Bone health and chronic kidney disease: another reason for partial nephrectomy?. Bone Heal. Urol. Patients 2014, 24:629-632.
66. Taxel P., Choksi P., Van Poznak C. The management of osteoporosis in breast cancer survivors. Maturitas 2012, 73:275-279.
67. Boonen S., Rosenberg E., Claessens F., Vanderschueren D., Papapoulos S. Inhibition of cathepsin K for treatment of osteoporosis. Curr. Osteoporos Rep. 2012, 10:73-79.
68. Bühling F., Röcken C., Brasch F., Hartig R., Yasuda Y., Saftig P., et al. Pivotal role of cathepsin K in lung fibrosis. Am. J. Pathol. 2004, 164:2203-2216.
69. Asagiri M., Hirai T., Kunigami T., Kamano S., Gober H.J., Okamoto K., et al. Cathepsin K-dependent toll-like receptor 9 signaling revealed in experimental arthritis. Science 2008, 319:624-627.
70. Kim K.W., Cho M.L., Oh H.J., Kim H.R., Kang C.M., Heo Y.M., et al. TLR-3 enhances osteoclastogenesis through upregulation of RANKL expression from fibroblast-like synoviocytes in patients with rheumatoid arthritis. Immunol. Lett. 2009, 124:9-17.
71. Abdollahi-Roodsaz S., Joosten L.A.B., Koenders M.I., van den Brand B.T., van de Loo F.A.J., van den Berg W.B. Local interleukin-1-driven joint pathology is dependent on toll-like receptor 4 activation. Am. J. Pathol. 2009, 175:2004-2013.
72. Hirabara S., Kojima T., Takahashi N., Hanabayashi M., Ishiguro N. Hyaluronan inhibits TLR-4 dependent cathepsin K and matrix metalloproteinase 1 expression in human fibroblasts. Biochem. Biophys. Res. Commun. 2013, 430:519-522.
73. Punturieri A., Filippov S., Allen E., Caras I., Murray R., Reddy V., et al. Regulation of elastinolytic cysteine proteinase activity in normal and cathepsin K-deficient human macrophages. J. Exp. Med. 2000, 192:789-799.
74. Dauth S., Sîrbulescu R.F., Jordans S., Rehders M., Avena L., Oswald J., et al. Cathepsin K deficiency in mice induces structural and metabolic changes in the central nervous system that are associated with learning and memory deficits. BMC Neurosci. 2011, 12:74.
75. Lendeckel U., Kähne T., Ten Have S., Bukowska A., Wolke C., Bogerts B., et al. Cathepsin K generates enkephalin from β-endorph a new mechanism with possible relevance for schizophrenia. Neurochem. Int. 2009, 54:410-417.
76. Hanahan D., Weinberg R. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
77. Gocheva V., Zeng W., Ke D., Klimstra D., Reinheckel T., Peters C., et al. Distinct roles for cysteine cathepsin genes in multistage tumorigenesis. Genes Dev. 2006, 20:543-556.
78. Joyce J.A., Baruch A., Chehade K., Meyer-Morse N., Giraudo E., Tsai F.-Y., et al. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 2004, 5:443-453.
79. Jedeszko C., Sloane B.F. Cysteine cathepsins in human cancer. Biol. Chem. 2004, 385:1017-1027.
80. Palermo C., Joyce J.A. Cysteine cathepsin proteases as pharmacological targets in cancer. Trends Pharmacol. Sci. 2008, 29:22-28.
81. Tan G.-J., Peng Z.-K., Lu J.-P., Tang F.-Q. Cathepsins mediate tumor metastasis. World J. Biol. Chem. 2013, 4:91-101.
82. Kos J., Vižin T., Pečar Fonović U., Pišlar A. Intracellular signaling by cathepsin X: molecular mechanisms and diagnostic and therapeutic opportunities in cancer. Semin. Cancer Biol. 2015, 31:76-83.
83. Krueger S., Kellner U., Buehling F., Roessner A. Cathepsin L antisense oligonucleotides in a human osteosarcoma cell line: effects on the invasive phenotype. Cancer Gene Ther. 2001, 8:522-528.
84. Bervar A., Zajc I., Sever N., Katunuma N., Sloane B.F., Lah T.T. Invasiveness of transformed human breast epithelial cell lines is related to cathepsin B and inhibited by cysteine proteinase inhibitors. Biol. Chem. 2005, 384:447-455.
85. Gole B., Durán Alonso M.B., Dolenc V., Lah T.T. Post-translational regulation of cathepsin B, but not of other cysteine cathepsins, contributes to increased glioblastoma cell invasiveness in vitro. Pathol. Oncol. Res. 2009, 15:711-723.
86. Kenig S., Durán Alonso M.B., Mueller M.M., Lah T.T. Glioblastoma and endothelial cells cross-talk, mediated by SDF-1, enhances tumour invasion and endothelial proliferation by increasing expression of cathepsins B, S, and MMP-9. Cancer Lett. 2010, 289:53-61.
87. Withana N.P., Blum G., Sameni M., Slaney C., Anbalagan A., Olive M.B., et al. Cathepsin B inhibition limits bone metastasis in breast cancer. Cancer Res. 2012, 72:1199-1209.
88. Lah T.T., Kokalj-Kunovar M., Štrukelj B., Pungerčar J., Barlič-Maganja D., Drobnič-Košorok M., et al. Stefins and lysosomal cathepsins B. L and D in human breast carcinoma. Int. J. Cancer 1992, 50:36-44.
89. Gole B., Huszthy P.C., Popović M., Jeruc J., Ardebili S.Y., Bjerkvig R., et al. The regulation of cysteine cathepsins and cystatins in human gliomas. Int. J. Cancer 2012, 131:1779-1789.
90. Colin C., Voutsinos-Porche B., Nanni I., Fina F., Metellus P., Intagliata D., et al. High expression of cathepsin B and plasminogen activator inhibitor type-1 are strong predictors of survival in glioblastomas. Acta Neuropathol. 2009, 118:745-754.
91. Brisson L., Reshkin S.J., Goré J., Roger S. PH regulators in invadosomal functioning: proton delivery for matrix tasting. Eur. J. Cell Biol. 2012, 91:847-860.
92. Sameni M., Moin K., Sloane B.F. Imaging proteolysis by living human breast cancer cells. Neoplasia 2001, 2:496-504.
93. Zhang L., Wang H., Xu J., Zhu J., Ding K. Inhibition of cathepsin S induces autophagy and apoptosis in human glioblastoma cell lines through ROS-mediated PI3K/AKT/mTOR/p70S6K and JNK signaling pathways. Toxicol. Lett. 2014, 228:248-259.
94. Kos J., Lah T.T. Cystatins in cancer. Human Stefins and Cystatins 2006, 153-165. Nova Sciences, New York. E. Žerovnik, N. Kopitar-Jerala, V. Uversky (Eds.).
95. Lah T.T., Obermajer N., Duran Alonso M.B., Kos J. Cysteine cathepsins and cystatins as cancer biomarkers. Cancer Degrad. 2008, 575-613. Springer Science+Business Media, New York. D. Edwards, G. Hoyer-Hansen, F. Blasi, B.F. Sloane (Eds.).
96. Jevnikar Z., Kos J. CSTA (cystatin A (stefin A)). Atlas Genet. Cytogenet. Oncol. Haematol. 2008, 13:403-405.
97. Boutté A.M., Friedman D.B., Bogyo M.S., Min Y., Yang L., Lin P.C. Identification of a myeloid-derived suppressor cell cystatin-like protein that inhibits metastasis. FASEB J. 2011, 25:2626-2637.
98. Vasiljeva O., Korovin M., Gajda M., Brodoefel H., Bojic L., Krüger A., et al. Reduced tumour cell proliferation and delayed development of high-grade mammary carcinomas in cathepsin B-deficient mice. Oncogene 2008, 27:4191-4199.
99. Sevenich L., Schurigt U., Sachse K., Gajda M., Werner F., Müller S., et al. Synergistic antitumor effects of combined cathepsin B and cathepsin Z deficiencies on breast cancer progression and metastasis in mice. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:2497-2502.
100. Brömme D., Okamoto K. Human cathepsin O2, a novel cysteine protease highly expressed in osteoclastomas and ovary molecular cloning, sequencing and tissue distribution. Biol. Chem. 1995, 376:379-384.
101. Lindeman J.H.N., Hanemaaijer R., Mulder A., Dijkstra P.D.S., Szuhai K., Brömme D., et al. Cathepsin K is the principal protease in giant cell tumor of bone. Am. J. Pathol. 2004, 165:593-600.
102. Husmann K., Muff R., Bolander M.E., Sarkar G., Born W., Fuchs B. Cathepsins and osteosarcoma: expression analysis identifies cathepsin K as an indicator of metastasis. Mol. Carcinog. 2008, 73:66-73.
103. Söderström M., Ekfors T., Böhling T., Aho A., Aro H.T., Vuorio E. Cysteine proteinases in chondrosarcomas. Matrix Biol. 2001, 19:717-725.
104. Martignoni G., Bonetti F., Chilosi M., Brunelli M., Segala D., Amin M.B., et al. Cathepsin K expression in the spectrum of perivascular epithelioid cell (PEC) lesions of the kidney. Mod. Pathol. 2012, 25:100-111.
105. Rao Q., Cheng L., Xia Q.-Y., Liu B., Li L., Shi Q.-L., et al. Cathepsin K expression in a wide spectrum of perivascular epithelioid cell neoplasms (PEComas): a clinicopathological study emphasizing extrarenal PEComas. Histopathology 2013, 62:642-650.
106. Martignoni G., Gobbo S., Camparo P., Brunelli M., Munari E., Segala D., et al. Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions. Mod. Pathol. 2011, 24:1313-1319.
107. Zheng G., Martignoni G., Antonescu C., Montgomery E., Eberhart C., Netto G., et al. A broad survey of cathepsin K immunoreactivity in human neoplasms. Am. J. Clin. Pathol. 2013, 139:151-159.
108. Argani P., Aulmann S., Illei P.B., Netto G.J., Ro J., Cho H.Y., et al. A distinctive subset of PEComas harbors TFE3 gene fusions. Am. J. Surg. Pathol. 2010, 34:1395-1406.
109. Littlewood-Evans A.J., Bilbe G., Bowler W.B., Farley D., Wlodarski B., Kokubo T., et al. The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res. 1997, 57:5386-5390.
110. Bühling F., Waldburg N., Gerber A., Häckel C., Krüger S., Reinhold D., et al. Cathepsin K expression in human lung. Adv. Exp. Med. Biol. 2000, 477:281-286.
111. Brubaker K.D., Vessella R.L., True L.D., Thomas R., Corey E. Cathepsin K mRNA and protein expression in prostate cancer progression. J. Bone Miner. Res. 2003, 18:222-230.
112. Le Gall C., Bellahcène A., Bonnelye E., Gasser J., Castronovo V., Green J., et al. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden. Cancer Res. 2007, 67:9894-9902.
113. Kleer C.G., Bloushtain-Qimron N., Chen Y.-H., Carrasco D., Hu M., Kraeft S.-K., et al. Epithelial and stromal cathepsin K and CXCL14 expression in breast tumor progression. Hum. Cancer Biol. 2008, 14:5357-5367.
114. Tumminello F.M., Flandina C., Crescimanno M., Leto G. Circulating cathepsin K and cystatin C in patients with cancer related bone disease: clinical and therapeutic implications. Biomed. Pharmacother. 2008, 62:130-135.
115. Chen B., Platt M.O. Multiplex zymography captures stage-specific activity profiles of cathepsins K. L, and S in human breast, lung, and cervical cancer. J. Transl. Med. 2011, 9:109.
116. Hill A., McFarlane S., Johnston P.G., Waugh D.J.J. CD44 signaling increases cathepsin K and MT1MMP expression to potentiate breast cancer cell invasion through collagen. Meet. Abstr. Breast Cancer Res. 2008, vol. 10 2008, S18. The Royal Society, London, UK.
117. Montgomery N., Hill A., McFarlane S., Neisen J., O'Grady A., Conlon S., et al. CD44 enhances invasion of basal-like breast cancer cells by up-regulating serine protease and collagen-degrading enzymatic expression and activity. Breast Cancer Res. 2012, 14:R84.
118. Balic M., Lin H., Young L., Hawes D., Giuliano A., McNamara G., et al. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin. Cancer Res. 2006, 12:5615-5621.
119. Cordes C., Bartling B., Simm A., Afar D., Lautenschläger C., Hansen G., et al. Simultaneous expression of Cathepsins B and K in pulmonary adenocarcinomas and squamous cell carcinomas predicts poor recurrence-free and overall survival. Lung Cancer 2009, 64:79-85.
120. Naumnik W., Nikliñska W., Ossoliñska M., Chyczewska E., Maria O., Chyczewska E. Serum cathepsin K and cystatin C concentration in patients with advanced non-small-cell lung cancer during chemotherapy. Folia Histochem. Cytobiol. 2009, 47:207-213.
121. Rapa I., Volante M., Cappia S., Rosas R., Scagliotti G.V., Papotti M. Cathepsin K is selectively expressed in the stroma of lung adenocarcinoma but not in bronchioloalveolar carcinoma. Am. J. Clin. Pathol. 2006, 125:847-854.
122. Wang R., Zhang J., Chen S., Lu M., Luo X., Yao S., et al. Tumor-associated macrophages provide a suitable microenvironment for non-small lung cancer invasion and progression. Lung Cancer 2011, 74:188-196.
123. Tsai J.Y., Lee M.J., Dah-Tsyr Chang M., Huang H. The effect of catalase on migration and invasion of lung cancer cells by regulating the activities of cathepsin S L, and K. Exp. Cell Res 2014, 323:28-40.
124. Podgorski I., Linebaugh B.E., Sloane B.F. Cathepsin K in the bone microenvironment: link between obesity and prostate cancer?. Biochem. Soc. Trans. 2007, 35:701-703.
125. Herroon M.K., Rajagurubandara E., Rudy D.L., Chalasani A., Hardaway A.L., Podgorski I. Macrophage cathepsin K promotes prostate tumor progression in bone. Oncogene 2013, 32:1580-1593.
126. Ishida M., Kojima F., Okabe H. Cathepsin K expression in basal cell carcinoma. J. Eur. Acad. Dermatol. Venereol. 2013, 27:e128-e130.
127. Quintanilla-Dieck M.J., Codriansky K., Keady M., Bhawan J., Rünger T.M. Cathepsin K in melanoma invasion. J. Invest. Dermatol. 2008, 128:2281-2288.
128. Yan X., Takahara M., Xie L., Oda Y., Nakahara T., Uchi H., et al. Stromal expression of cathepsin K in squamous cell carcinoma. J. Eur. Acad. Dermatol. Venereol. 2011, 25:362-365.
129. Xie L., Moroi Y., Hayashida S., Tsuji G., Takeuchi S., Shan B. Cathepsin K-upregulation in fibroblasts promotes matrigel invasive ability of squamous cell carcinoma cells via tumor-derived IL-1a. J. Dermatol. Sci. 2011, 61:45-50.
130. Yuan Y., Xue L., Fan H. Screening of differentially expressed genes related to esophageal squamous cell carcinoma and functional analysis with DNA microarrays. Int. J. Oncol. 2014, 44:1163-1170.
131. Bitu C.C., Kauppila J.H., Bufalino A., Nurmenniemi S., Teppo S., Keinänen M., et al. Cathepsin K is present in invasive oral tongue squamous cell carcinoma in vivo and in vitro. PLOS ONE 2013, 8:e70925.
132. Szumilo J., Burdan F., Zinkiewicz K., Dudka J., Klepacz R., Dabrowski A., et al. Expression of syndecan-1 and cathepsins D and K in advanced esophageal squamous cell carcinoma. Folia Histochem. Cytobiol. 2009, 47:571-578.
133. Martignoni G., Pea M., Gobbo S., Brunelli M., Bonetti F., Segala D., et al. Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas. Mod. Pathol. 2009, 22:1016-1022.
134. Ren G., Tian Q., An Y., Feng B., Lu Y., Liang J., et al. Coronin 3 promotes gastric cancer metastasis via the up-regulation of MMP-9 and cathepsin K. Mol. Cancer 2012, 11:67.
135. Rao Q., Wang Y., Xia Q.-Y., Shi S.-S., Shen Q., Tu P., et al. Cathepsin K in the immunohistochemical diagnosis of melanocytic lesions. Int. J. Clin. Exp. Pathol. 2014, 7:1132-1139.
136. Verbovšek U., Motaln H., Rotter A., Atai N.A., Gruden K., Van Noorden C.J.F., et al. Expression analysis of all protease genes reveals cathepsin K to be overexpressed in glioblastoma. PLOS ONE 2014, 9:e111819.
137. Hira V.V.V., Ploegmakers K.J., Verbovšek U., Roing C.S., Aronica E.M.A., Tigchelaar W., et al. CD133+ and nestin+ glioma stem-like cells reside around CD31+ arterioles in niches that express SDF-1α. CXCR4, osteopontin and cathepsin K. J. Histochem. Cytochem. 2015, 63:481-493.
138. Sanchez-Sweatman O.H., Lee J., Orr F.W., Singh G. Direct osteolysis induced by metastatic murine melanoma cells: role of matrix metalloproteinases. Eur. J. Cancer 1997, 33:918-925.
139. Motyckova G., Weilbaecher K.N., Horstmann M., Rieman D.J., Fisher D.Z., Fisher D.E. Linking osteopetrosis and pycnodysostosis: regulation of cathepsin K expression by the microphthalmia transcription factor family. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:5798-5803.
140. Paget S. The distribution of secondary growths in cancer of breast. Lancet 1889, 1:571-573.
141. Deng X., He G., Liu J., Luo F., Peng X., Tang S., et al. Recent advances in bone-targeted therapies of metastatic prostate cancer. Cancer Treat. Rev. 2014, 40:730-738.
142. Molina E.S., Pillat M.M., Moura-Neto V., Lah T.T., Ulrich H. Glioblastoma stem-like cells: approaches for isolation and characterization. J. Cancer Stem Cell Res. 2014, 2:e1007.
143. Vermeulen L., Snippert H.J. Stem cell dynamics in homeostasis and cancer of the intestine. Nat. Rev. Cancer 2014, 14:468-480.
144. Borovski T., De Sousa E., Melo F., Vermeulen L., Medema J.P. Cancer stem cell niche: the place to be. Cancer Res. 2011, 71:634-639.
145. Barnes G.L., Hebert K.E., Kamal M., Javed A., Einhorn T.A., Lian J.B., et al. Fidelity of runx2 activity in breast cancer cells is required for the generation of metastases-associated osteolytic disease. Cancer Res. 2004, 64:4506-4513.
146. Tomita A., Kasaoka T., Inui T., Toyoshima M., Nishiyama H., Saiki H., et al. Human breast adenocarcinoma (MDA-231) and human lung squamous cell carcinoma (Hara) do not have the ability to cause bone resorption by themselves during the establishment of bone metastasis. Clin. Exp. Metastasis 2008, 25:437-444.
147. Bossard M.J., Tomaszek T.A., Thompson S.K., Amegadzie B.Y., Hanning C.R., Jones C., et al. Proteolytic activity of human osteoclast cathepsin K. J. Biol. Chem. 1996, 271:12517-12524.
148. Chiodoni C., Colombo M.P., Sangaletti S. Matricellular proteins: from homeostasis to inflammation, cancer, and metastasis. Cancer Metastasis Rev. 2010, 29:295-307.
149. Raposo T.P., Beirão B.C.B., Pang L.Y., Queiroga F.L., Argyle D.J. Inflammation and cancer: till death tears them apart. Vet. J. 2015, 205:161-174.
150. Atai N.A., Balaj L., Van Veen H., Breakefield X.O., Jarzyna P.A., Van Noorden C.J.F., et al. Heparin blocks transfer of extracellular vesicles between donor and recipient cells. J. Neurooncol. 2013, 115:343-351.
151. Wurdinger T., Deumelandt K., Van DerVliet H.J., De Gruijl T.D. Mechanisms of cross-talk between glioma and myeloid cells: how to break a vicious cycle. BBA - Rev. Cancer 2014, 1846:1-32.
152. Nakano I., Garnier D., Minata M., Rak J. Extracellular vesicles in the biology of brain tumour stem cells - implications for inter-cellular communication, therapy and biomarker development. Semin. Cell Dev. Biol. 2015, 40:1-10.
153. Schichor C., Albrecht V., Korte B., Buchner A., Riesenberg R., Mysliwietz J., et al. Mesenchymal stem cells and glioma cells form a structural as well as a functional syncytium in vitro. Exp. Neurol. 2012, 234:208-219.
154. Motaln H., Schichor C., Lah T.T. Human mesenchymal stem cells and their use in cell-based therapies. Cancer 2010, 116:2519-2530.
155. Tajnšek U., Motaln H., Levicar N., Rotter A., Lah T.T. The duality of stem cells: Double-edged sword in tumor evolution and treatment. Trends in Stem Cell Proliferation and Cancer Research 2013, 391-433. Springer Science+Business Media, Dordrecht. R.R. Resende, H. Ulrich (Eds.).
156. Arango-Rodriguez M.L. Could cancer and infection be adverse effects of mesenchymal stromal cell therapy?. World J. Stem Cells 2015, 7:408-417.
157. Godat E., Hervé-Grépinet V., Veillard F., Lecaille F., Belghazi M., Brömme D., et al. Regulation of cathepsin K activity by hydrogen peroxide. Biol. Chem. 2008, 389:1123-1126.
158. Hervé-Grépinet V., Veillard F., Godat E., Heuzé-Vourc'h N., Lecaille F., Lalmanach G. Extracellular catalase activity protects cysteine cathepsins from inactivation by hydrogen peroxide. FEBS Lett. 2008, 582:1307-1312.
159. Skrzydlewska E., Sulkowska M., Koda M., Sulkowski S. Proteolytic-antiproteolytic balance and its regulation in carcinogenesis. World J. Gastroenterol. 2005, 11:1251-1266.
160. Suoranta S., Manninen H., Koskenkorva P., Könönen M., Laitinen R., Lehesjoki A.-E., et al. Thickened skull, scoliosis and other skeletal findings in Unverricht-Lundborg disease link cystatin B function to bone metabolism. Bone 2012, 51:1016-1024.
161. Castiglioni T., Merino M.J., Elsner B., Lah T.T., Sloane B.F., Emmert-Buck M.R. Immunohistochemical analysis of cathepsins D, B, and L in human breast cancer. Hum. Pathol. 1994, 25:857-862.
162. Kos J., Šmid A., Krašovec M., Svetic B., Lenarčič B., Vrhovec I., et al. Lysosomal proteases cathepsins D, B, H, L and their inhibitors stefins A and B in head and neck cancer. Biol. Chem. 1995, 376:401-405.
163. Ledakis P., Tester W.T., Rosenberg N., Romero-Fischmann D., Daskal I., Lah T.T. Cathepsins D, B, and L in malignant human lung tissue. Clin. Cancer Res. 1996, 2:561-568.
164. Strojnik T., Kos J., Židanik B., Goluh R., Lah T.T. Cathepsin B immunohistochemical staining in tumor and endothelial cells is a new prognostic factor for survival in patients with brain tumors. Clin. Cancer Res. 1999, 5:559-567.
165. Levicar N., Kos J., Blejec A., Golouh R., Vrhovec I., Frkovic-Grazio S., et al. Comparison of potential biological markers cathepsin B, cathepsin L, stefin A and stefin B with urokinase and plasminogen activator inhibitor-1 and clinicopathological data of breast carcinoma patients. Cancer Detect. Prev. 2002, 26:42-49.
166. Strojnik T., Kavalar R., Trinkaus M., Lah T.T. Cathepsin L in glioma progression: comparison with cathepsin B. Cancer Detect. Prev. 2005, 29:448-455.
167. Flannery T., McQuaid S., McGoohan C., McConnell R.S., McGregor G., Mirakhur M., et al. Cathepsin S expression: an independent prognostic factor in glioblastoma tumours - a pilot study. Int. J. Cancer 2006, 119:854-860.
168. Hazen L.G.M., Bleeker F.E., Lauritzen B., Bahns S., Song J., Jonker A., et al. Comparative localization of cathepsin B protein and activity in colorectal cancer. J. Histochem. Cytochem. 2000, 48:1421-1430.
169. Vižin T., Christensen I., Wilhelmsen M., Nielsen H., Kos J. Prognostic and predictive value of cathepsin X in serum from colorectal cancer patients. BMC Cancer 2014, 14:259.
170. Bunatova K., Obermajer N., Kotyza J., Pesek M., Kos J. Levels of cathepsins S and H in pleural fluids of inflammatory and neoplastic origin. Int. J. Biol. Markers 2009, 24:47-51.
171. Kos J., Werle B., Lah T.T., Brunner N. Cysteine proteinases and their inhibitors in extracellular fluids: markers for diagnosis and prognosis in cancer. Int. J. Biol. Markers 2000, 15:84-89.
172. Kolwijck E., Kos J., Obermajer N., Span P.N., Thomas C.M.G., Massuger L.F.A.G., et al. The balance between extracellular cathepsins and cystatin C is of importance for ovarian cancer. Eur. J. Clin. Invest. 2010, 40:591-599.
173. Turk B. Targeting proteases: successes, failures and future prospects. Nat. Rev. Drug Discov. 2006, 5:785-799.
174. Kos J., Obermajer N., Doljak B., Kocbek P., Kristl J. Inactivation of harmful tumour-associated proteolysis by nanoparticulate system. Int. J. Pharm. 2009, 381:106-112.
175. Gaumann A., Hansen T., Köhler H.H., Kommoss F., Mann W., Maurer J., et al. The expression of cathepsins in osteoclast-like giant cells of an anaplastic thyroid carcinoma with tracheal perforation. Pathol. Res. Pract. 2001, 197:257-262.
176. Mikosch P., Kerschan-Schindl K., Woloszczuk W., Stettner H., Kudlacek S., Kresnik E., et al. High cathepsin K levels in men with differentiated thyroid cancer on suppressive l-thyroxine therapy. Thyroid 2008, 18:27-33.
177. Everts V., Beertsen W., Schroder R. Effects of proteinase inhibitors leupeptin and E-64 on osteoclastic bone resorption. Calcif. Tissue Int. 1988, 43:172-178.
178. Lecaille F., Kaleta J., Brömme D. Human and parasitic papain-like cysteine proteases: their role in physiology and pathology and recent developments in inhibitor design. Chem. Rev. 2002, 102:4459-4488.
179. Yamashita D.S., Dodds R.A. Cathepsin K and the design of inhibitors of cathepsin K. Curr. Pharm. Des. 2000, 6:1-24.
180. Yasuda Y., Kaleta J., Brömme D. The role of cathepsins in osteoporosis and arthritis: rationale for the design of new therapeutics. Adv. Drug Deliv. Rev. 2005, 57:973-993.
181. Kim T.-S., Tasker A.S. Non-covalent cathepsin K inhibitors for the treatment of osteoporosis. Curr. Top. Med. Chem. 2006, 6:355-360.
182. Falgueyret J.-P., Desmarais S., Oballa R., Black W.C., Cromlish W., Khougaz K., et al. Lysosomotropism of basic cathepsin K inhibitors contributes to increased cellular potencies against off-target cathepsins and reduced functional selectivity. J. Med. Chem. 2005, 48:7535-7543.
183. Black W.C., Percival M.D. The consequences of lysosomotropism on the design of selective cathepsin K inhibitors. ChemBioChem 2006, 7:1525-1535.
184. Li C.S., Deschenes D., Desmarais S., Falgueyret J.-P., Gauthier J.Y., Kimmel D.B., et al. Identification of a potent and selective non-basic cathepsin K inhibitor. Bioorg. Med. Chem. Lett. 2006, 16:1985-1989.
185. Desmarais S., Black W.C., Oballa R., Lamontagne S., Riendeau D., Tawa P., et al. Effect of cathepsin K inhibitor basicity on in vivo off-target. Mol. Pharmacol. 2008, 73:1147-1156.
186. Wijkmans J., Gossen J. Inhibitors of cathepsin K: a patent review (2004-2010). Expert Opin. Ther. Pat. 2011, 21:1611-1629.
187. Schuiling K.D., Robinia K., Nye R. Osteoporosis update. J. Midwifery Women's Heal. 2011, 56:615-627.
188. Duong L.T.L.T., Wesolowski G.A., Leung P., Oballa R., Pickarski M. Efficacy of a cathepsin K inhibitor in a preclinical model for prevention and treatment of breast cancer bone metastasis. Mol. Cancer Ther. 2014, 13:2898-2909.
189. Chapurlat R.D. Odanacatib: a review of its potential in the management of osteoporosis in postmenopausal women. Ther. Adv. Musculoskelet. Dis. 2015, 7:103-109.
190. Merck Merck announces data from pivotal phase 3 fracture outcomes study for odanacatib, an investigational oral, once-weekly treatment for osteoporosis. Merck Newsroom Home 2014, http://www.mercknewsroom.com/news-release/research-and-development-news/merck-announces-data-pivotal-phase-3-fracture-outcomes-st (accessed 19.02.15).
191. Engelke K., Nagase S., Fuerst T., Small M., Kuwayama T., Deacon S., et al. The effect of the cathepsin K inhibitor ONO-5334 on trabecular and cortical bone in postmenopausal osteoporosis: the OCEAN study. J. Bone Miner. Res. 2014, 29:629-638.
192. ONO 5334. AdisInsight, Springer 2015. (accessed 17.08.15). http://adisinsight.springer.com/drugs/800024483.
193. Eastell R., Nagase S., Ohyama M., Small M., Sawyer J., Boonen S., et al. Safety and efficacy of the cathepsin K inhibitor ONO-5334 in postmenopausal osteoporosis: the OCEAN study. J. Bone Miner. Res. 2011, 26:1303-1312.
194. Grabowska U., Chambers T.J., Shiroo M. Recent developments in cathepsin K inhibitor design. Curr. Opin. Drug Discov. Dev. 2005, 8:619-630.
195. Palmer J.T., Bryant C., Wang D.X., Davis D.E., Setti E.L., Rydzewski R.M., et al. Design and synthesis of tri-ring P 3 benzamide-containing aminonitriles as potent, selective, orally effective inhibitors of cathepsin K. J. Med. Chem. 2005, 48:7520-7534.
196. Le Gall C., Bonnelye E., Clézardin P. Cathepsin K inhibitors as treatment of bone metastasis. Curr. Opin. Support. Palliat. Care 2008, 2:218-222.
197. Jensen A.B., Wynne C., Ramirez G., He W., Song Y., Berd Y., et al. The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial. Clin. Breast Cancer 2010, 10:452-458.
198. Odanacatib. AdisInsight, Springer 2015. (accessed 17.08.15). http://adisinsight.springer.com/drugs/800024552.